Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 178-193

  Johannes, Ludger ^a   Lucchino, Marco ^a  

^a CNRS UMR3666   (France)

Author keywords

checkpoint inhibitor; immunotherapy; miRNA; oligonucleotides; Shiga toxin B subunit; siRNA

Indexed keywords

CATIONIC PEPTIDE; CELL PENETRATING PEPTIDE; HYDROXYL GROUP; LIPID; NANOPARTICLE; OLIGONUCLEOTIDE; PEPTIDE; PHOSPHOROTHIOIC ACID; POLYLYSINE; POLYMER; PROTAMINE; PROTEIN; RIBOSE; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; MICRORNA; MORPHOLINO OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEPTIDE NUCLEIC ACID; SMALL INTERFERING RNA;

CHEMICAL MODIFICATION; CYTOSOL; DRUG DELIVERY SYSTEM; ENDOSOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RNA TRANSPORT; AMYLOIDOSIS; ANIMAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

AMYLOIDOSIS; ANIMALS; BIOLOGICAL TRANSPORT; CELL-PENETRATING PEPTIDES; CYTOSOL; ENDOSOMES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIPIDS; MICRORNAS; MORPHOLINOS; NANOPARTICLES; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE NUCLEIC ACIDS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RNA, SMALL INTERFERING;

EID: 85048355854     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2017.0716     Document Type: Review

References (175)

1. Castanotto D and JJ Rossi. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433.
2. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chappell, K Schmidt, C Zhao, M Aghajan, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42: 8796-8807.
3. Dowdy SF. (2017). Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35:222-229.
4. Chakraborty C, AR Sharma, G Sharma, CGP Doss and SS Lee. (2017). Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids 8:132-143.
5. Ohrt T, J Muetze, P Svoboda and P Schwille. (2012). Intracellular localization and routing of miRNA and RNAi pathway components. Curr Top Med Chem 12:79-88.
6. Yang N, NR Ekanem, CA Sakyi and SD Ray. (2015). Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev 81:62-74.
7. Brengues M, D Teixeira and R Parker. (2005). Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. Science 310:486-489.
8. Oliveira S, G Storm and RM Schiffelers. (2006). Targeted delivery of siRNA. J Biomed Biotechnol 2006:63675.
9. Beaudet AL and L Meng. (2016). Gene-targeting pharmaceuticals for single-gene disorders. Hum Mol Genet 25: R18-R26.
10. Cerritelli SM and RJ Crouch. (2009). Ribonuclease H: the enzymes in eukaryotes. FEBS J 276:1494-1505.
11. Chi X, P Gatti and T Papoian. (2017). Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today 22:823-833.
12. El-Aneed A. (2004). An overview of current delivery systems in cancer gene therapy. J Control Release 94:1-14.
13. Yin H, KJ Kauffman and DG Anderson. (2017). Delivery technologies for genome editing. Nat Rev Drug Discov 16:387-399.
14. Ju Z and W Sun. (2017). Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles. Drug Deliv 24:1898-1908.
15. Karimi M, H Mirshekari, SM Moosavi Basri, S Bahrami, M Moghoofei and MR Hamblin. (2016). Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. Adv Drug Deliv Rev 106:45-62.
16. Rettig GR and MA Behlke. (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20:483-512.
17. Bennett CF and EE Swayze. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
18. Kaczmarek JC, PS Kowalski and DG Anderson. (2017). Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:60.
19. Eckstein F. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev 10:117-121.
20. Stein CA and D Castanotto. (2017). FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069-1075.
21. Crooke ST, S Wang, TA Vickers, W Shen and X Liang. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 35:230-237.
22. Stein CA, JB Hansen, J Lai, SJ Wu, A Voskresenskiy, A Høg, J Worm, M Hedtjärn, N Souleimanian, et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3.
23. Castanotto D, M Lin, C Kowolik, LA Wang, XQ Ren, HS Soifer, T Koch, BR Hansen, H Oerum, et al. (2015). A cytoplasmic pathway for gapmer antisense oligonucleotidemediated gene silencing in mammalian cells. Nucleic Acids Res 43:9350-9361.
24. Prakash TP, CR Allerson, P Dande, TA Vickers, N Sioufi, R Jarres, BF Baker, EE Swayze, RH Griffey and B Bhat. (2005). Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 48:4247-4253.
25. Braasch DA, S Jensen, Y Liu, K Kaur, K Arar, MA White and DR Corey. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42:7967-7975.
26. Chiu Y-L and MR Tariq. (2003). siRNA function in RNAi: a chemical modification analysis. RNA 9:1034-1048.
27. Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518-6548.
28. Tatiparti K, S Sau, SK Kashaw and AK Iyer. (2017). siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials 7:1-17.
29. Amarzguioui M, T Holen, E Babaie and H Prydz. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589-595.
30. Czauderna F, M Fechtner, S Dames, H Aygün, A Klippel, GJ Pronk, K Giese and J Kaufmann. (2003). Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705-2716.
31. Ozcan G, B Ozpolat, RL Coleman, AK Sood and G Lopezberestein. (2015). Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108-119.
32. Amarzguioui M, P Lundberg, E Cantin, J Hagstrom, MA Behlke and JJ Rossi. (2006). Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc 1:508-517.
33. Allerson CR, N Sioufi, R Jarres, TP Prakash, N Naik, A Berdeja, L Wanders, RH Griffey, EE Swayze and B Bhat. (2005). Fully 2′-modified oligonucleotide duplexes with improved in vitro unmodified small interfering RNA. J Med Chem 48:901-904.
34. Hassler MR, AA Turanov, JF Alterman, RA Haraszti, H Coles, MF Osborn, D Echeverria, M Nikan, WE Salomon, et al. (2018). Comparison of partially and fully chemicallymodified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res 46:2185-2196.
35. Fitzgerald K, S White, A Borodovsky, BR Bettencourt, A Strahs, V Clausen, P Wijngaard, JD Horton, J Taubel, et al. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41-51.
36. Nair JK, JLS Willoughby, A Chan, K Charisse, MR Alam, Q Wang, M Hoekstra, P Kandasamy, AV Kel'in AV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAimediated gene silencing. J Am Chem Soc 136:16958-16961.
37. Mani S, S Goel, M Nesterova, RM Martin, JM Grindel, ML Rothenberg, R Zhang, G Tortora and YS Cho-Chung. (2003). Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci 1002:252-262.
38. Chi KN, E Eisenhauer, L Fazli, EC Jones, SL Goldenberg, J Powers, D Tu and ME Gleave. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX- 011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97:1287-1296.
39. Sewell KLEA, RS Geary, BF Baker, JM Glover, TGK Mant, RZ Yu, JA Tami and FA Dorr. (2002). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343.
40. Raal FJ, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, RH Lachmann, D Gaudet, JL Tan, et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998-1006.
41. Chiriboga CA, KJ Swoboda, BT Darras, ST Iannaccone, J Montes, DC De Vivo, DA Norris, CF Bennett and KM Bishop. (2016). Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86:890-897.
42. Jolly P, P Estrela and M Ladomery. (2016). Oligonucleotidebased systems: DNA, microRNAs, DNA/RNA aptamers. Essays Biochem 60:27-35.
43. Hagedorn PH, R Persson, ED Funder, N Albæk, SL Diemer, DJ Hansen, MR Møller, N Papargyri, H Christiansen, et al. (2018). Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today 23:101-114.
44. Summerton J. (1999). Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489:141-158.
45. Järver P, T Coursindel, SEL Andaloussi, C Godfrey, MJ Wood and MJ Gait. (2012). Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol Ther Nucleic Acids 1:e27.
46. Lim KRQ, R Maruyama and T Yokota. (2017). Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther 11:533-545.
47. Egholm M, O Buchardt, L Christensen, C Behrens, SM Freier, DA Driver, RH Berg, SK Kim, B Norden and PE Nielsen. (1993). PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365:566-568.
48. De Mesmaeker A, KH Altmann, A Waldner and S Wendeborn. (1995). Backbone modifications in oligonucleotides and peptide nucleic acid systems. Curr Opin Struct Biol 5:343-355.
49. Lebreton J, A Waldner, V Fritsch, RM Wolf and A De Mesmaeker. (1994). Comparison of two amides as backbone replacement of the phosphodiester linkage in oligodeoxynucleotides. Tetrahedron Lett 35:5225-5228.
50. Sanghvi YS, EE Swayze, D Peoc'h, B Bhat and S Dimock. (1997). Concept, discovery and development of MMI linkage: story of a novel linkage: for antisense constructs. Nucleosides Nucleotides 16:907-916.
51. Zhang J, JT Shaw and MD Matteucci. (1999). Synthesis and hybridization property of an oligonucleotide containing a 3′-thioformcetal linked pentathymidylate. Bioorg Med Chem Lett 9:319-322.
52. Komarova Y and AB Malik. (2010). Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 72:463-493.
53. Sarin H. (2010). Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2:14.
54. Kang L, RF Wang, P Yan, M Liu, CL Zhang, MM Yu, YG Cui and XJ Xu. (2010). Noninvasive visualization of RNA delivery with 99mTc-radiolabeled small-interference RNA in tumor xenografts. J Nucl Med 51:978-986.
55. Zheng M, D Librizzi, A Kiliç, Y Liu, H Renz, OM Merkel and T Kissel. (2012). Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graftpolycaprolactone- block-poly(ethylene glycol) copolymers. Biomaterials 33:6551-6558.
56. Sehgal A, A Vaishnaw and K Fitzgerald. (2013). Liver as a target for oligonucleotide therapeutics. J Hepatol 59: 1354-1359.
57. Juliano RL, X Ming, K Carver and B Laing. (2014). Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther 24:101-113.
58. Shukla RS, B Qin and K Cheng. (2014). Peptides used in the delivery of small noncoding RNA. Mol Pharmacol 11: 3395-3408.
59. Yogasundaram H, MS Bahniuk, HD Singh, HM Aliabadi, H Uludaǧ and LD Unsworth. (2012). BSA nanoparticles for siRNA delivery: coating effects on nanoparticle properties, plasma protein adsorption, and in vitro siRNA delivery. Int J Biomater 2012:584060.
60. Cavallaro G, C Sardo, EF Craparo, B Porsio and G Giammona. (2017). Polymeric nanoparticles for siRNA delivery: production and applications. Int J Pharm 525: 313-333.
61. Lee SH, YY Kang, HE Jang and H Mok. (2016). Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv Drug Deliv Rev 104:78-92.
62. Wagner E, M Zenke, M Cotten, H Beug and ML Birnstiel. (1990). Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci U S A 87: 3410-3414.
63. Martin ME and KG Rice. (2007). Peptide-guided gene delivery. AAPS J 9: E18-E29.
64. Kaminskas LM, BJ Boyd, P Karellas, SA Henderson, MP Giannis, GY Krippner and CJH Porter. (2007). Impact of surface derivatization of poly-l-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition. Mol Pharmacol 4:949-961.
65. Lee H, JH Jeong and TG Park. (2002). PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicity. J Control Release 79:283-291.
66. Balhorn R. (2007). The protamine family of sperm nuclear proteins. Genome Biol 8:227.
67. Kallen KJ, R Heidenreich, M Schnee, B Petsch, T Schlake, A Thess, P Baumhof, B Scheel, SD Koch and M Fotin-Mleczek. (2013). A novel, disruptive vaccination technology. Hum Vaccines Immunother 9:2263-2276.
68. Peer D, EJ Park, Y Morishita, CV Carman and M Shimaoka. (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319:627-630.
69. Shukla RS, W Tai, R Mahato, W Jin and K Cheng. (2013). Development of streptavidin-based nanocomplex for siRNA delivery. Mol Pharmacol 10:4534-4545.
70. Song E, P Zhu, S-K Lee, D Chowdhury, S Kussman, DM Dykxhoorn, Y Feng, D Palliser, DB Weiner, et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709-717.
71. Miele L. (2006). Notch signaling. Clin Cancer Res 12: 1074-1079.
72. Su Y, L Yu, N Liu, Z Guo, G Wang, J Zheng, M Wei, H Wang, A Yang, W Qin and W Wen. (2013). PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Cancer Lett 338:282-291.
73. Yao Y, T Sun, S Huang, S Dou, L Lin, J Chen, J Ruan, C Mao, F Yu, et al. (2012). Targeted delivery of PLK1- siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 4:130ra148.
74. Peer D, P Zhu, CV Carman, J Lieberman and M Shimaoka. (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 104:4095-4100.
75. Owens DR. (2011). Insulin preparations with prolonged effect. Diabetes Technol Ther 13:S5-S14.
76. Greinacher A, T Thiele and K Selleng. (2015). Reversal of anticoagulants: an overview of current developments. Thromb Haemost 113:931-942.
77. He H, J Ye, E Liu, Q Liang, Q Liu and VC Yang. (2014). Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide. J Control Release 193:63-73.
78. Lee LM, LC Chang, S Wrobleski, TW Wakefield and VC Yang. (2001). Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci 3:E19.
79. Byun Y, VK Singh and VC Yang. (1999). Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb Res 94:53-61.
80. Choi YS, JY Lee, JS Suh, YM Kwon, SJ Lee, JK Chung, DS Lee, VC Yang, CP Chung and YJ Park. (2010). The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 31:1429-1443.
81. Ye J, E Liu, J Gong, J Wang, Y Huang, H He and VC Yang. (2017). High-yield synthesis of monomeric LMWP(CPP)- siRNA covalent conjugate for effective cytosolic delivery of siRNA. Theranostics 7:2495-2508.
82. Guidotti G, L Brambilla and D Rossi. (2017). Cellpenetrating peptides: from basic research to clinics. Trends Pharmacol Sci 38:406-424.
83. Futaki S and I Nakase. (2017). Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization. Acc Chem Res 50:2449-2456.
84. Zahid M and PD Robbins. (2015). Cell-type specific penetrating peptides: therapeutic promises and challenges. Molecules 20:13055-13070.
85. Bartz R, H Fan, J Zhang, N Innocent, C Cherrin, SC Beck, Y Pei, A Momose, V Jadhav, et al. (2011). Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. Biochem J 435:475-487.
86. Summerton JE. (2005). Endo-Porter: a novel reagent for safe, effective delivery of substances into cells. Ann N Y Acad Sci 1058:62-75.
87. Margus H, K Padari and M Pooga. (2012). Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20:525-533.
88. Tajik-Ahmadabad B, A Polyzos, F Separovic and F Shabanpoor. (2017). Amphiphilic lipopeptide significantly enhances uptake of charge-neutral splice switching morpholino oligonucleotide in spinal muscular atrophy patientderived fibroblasts. Int J Pharm 532:21-28.
89. Moulton HM. (2013). In vivo delivery of morpholino oligos by cell-penetrating peptides. Curr Pharm Des 19: 2963-2969.
90. Aslesh T, R Maruyama and T Yokota. (2018). Skipping multiple exons to treat DMD-promises and challenges. Biomedicines 6:1-12.
91. Echigoya Y, A Nakamura, T Nagata, N Urasawa, KRQ Lim, N Trieu, D Panesar, M Kuraoka, HM Moulton, et al. (2017). Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114:4213-4218.
92. Moulton HM and JD Moulton. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798:2296-2303.
93. Akinc A, M Thomas, AM Klibanov and R Langer. (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7:657-663.
94. Benjaminsen RV, MA Mattebjerg, JR Henriksen, SM Moghimi and TL Andresen. (2013). The possible "proton sponge" effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther 21:149-157.
95. Kunath K, A VonHarpe, D Fischer, H Petersen, U Bickel, K Voigt and T Kissel. (2003). Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecularweight polyethylenimine. J Control Release 89:113-125.
96. Arima H, K Motoyama and T Higashi. (2011). Potential use of polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for siRNA. Pharmaceuticals (Basel) 5:61-78.
97. Howard KA, UL Rahbek, X Liu, CK Damgaard, SZ Glud, M Andersen, MB Hovgaard, A Schmitz, JR Nyengaard, F Besenbacher and J Kjems. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14:476-484.
98. Adams D, OB Suhr, PJ Dyck, WJ Litchy, RG Leahy, J Chen, J Gollob and T Coelho. (2017). Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17:181.
99. Zatsepin TS, YV Kotelevtsev and V Koteliansky. (2016). Lipid nanoparticles for targeted siRNA delivery-going from bench to bedside. Int J Nanomater 11:3077-3086.
100. Lorenzer C, M Dirin, A Winkler, V Baumann and J Winkler. (2015). Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 203:1-15.
101. Xiao K, Y Li, J Luo, JS Lee, W Xiao, AM Gonik, RG Agarwal and KS Lam. (2011). The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32:3435-3446.
102. Otsuka H, Y Nagasaki and K Kataoka. (2012). PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 64:246-255.
103. Coelho T, D Adams, A Silva, P Lozeron, P Hawkins, T Mant, J Perez, J Chiesa, S Warrington, et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819-829.
104. Tabernero J, GI Shapiro, PM Lorusso, A Cervantes, GK Schwartz, GJ Weiss, L Paz-Ares, DC Cho, JR Infante, et al. (2013). First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406-417.
105. Wahl O, M Oswald, L Tretzel, E Herres, J Arend and T Efferth. (2011). Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 18:3136-3155.
106. Balakumar C, M Ramesh, CL Tham, SP Khathi, F Kozielski, C Srinivasulu, GA Hampannavar, N Sayyad, ME Soliman and R Karpoormath. (2017). Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents. J Biomol Struct Dyn 1-77.
107. Prabhakar U, H Maeda, RK Jain, EM Sevick-Muraca, W Zamboni, OC Farokhzad, ST Barry, A Gabizon, P Grodzinski and DC Blakey. (2013). Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412-2417.
108. Titze-de-almeida R, C David and SS Titze-de-almeida. (2017). The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res 34:1339-1363.
109. Guo P, O Coban, NM Snead, J Trebley, S Hoeprich, S Guo and Y Shu. (2010). Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 62:650-666.
110. Hu Q, H Li, L Wang, H Gu and C Fan. (2018). DNA nanotechnology-enabled drug delivery systems. Chem Rev [Epub ahead of print]; DOI:10.1021/acs.chemrev.7b00663.
111. Lee H, AKR Lytton-jean, Y Chen, KT Love, AI Park, ED Karagiannis, A Sehgal, W Querbes, CS Zurenko, et al. (2012). Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 7:389-393.
112. Haque F, F Pi, Z Zhao, S Gu, H Hu, H Yu and P Guo. (2018). RNA versatility, flexibility, and thermostability for practice in RNA nanotechnology and biomedical applications. Wiley Interdiscip Rev RNA 9:1-17.
113. Guo P. (2010). The emerging field of RNA nanotechnology. Nat Nanotechnol 5:833-842.
114. Shu Y, D Shu, F Haque and P Guo. (2013). Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat Protoc 8:1635-1659.
115. Guo S, F Huang and P Guo. (2006). Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther 13:814-820.
116. Beck A, L Goetsch, C Dumontet and N Corvaïa. (2017). Strategies and challenges for the next generation of antibodydrug conjugates. Nat Rev Drug Discov 16:315-337.
117. Cuellar TL, D Barnes, C Nelson, J Tanguay, SF Yu, X Wen, SJ Scales, J Gesch, D Davis, et al. (2015). Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res 43:1189-1203.
118. Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
119. Katakowski JA, G Mukherjee, SE Wilner, KE Maier, MT Harrison, TP DiLorenzo, M Levy and D Palliser. (2016). Delivery of siRNAs to dendritic cells using DEC205- targeted lipid nanoparticles to inhibit immune responses. Mol Ther 24:146-155.
120. Hilgenbrink AR and PS Low. (2005). Folate receptormediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94:2135-2146.
121. Dohmen C, T Fröhlich, U Lächelt, I Röhl, H-P Vornlocher, P Hadwiger and E Wagner. (2012). Defined folate-PEGsiRNA conjugates for receptor-specific gene silencing. Mol Ther Nucleic Acids 1:e7.
122. Li JM, YY Wang, W Zhang, H Su, LN Ji and ZW Mao. (2013). Low-weight polyethylenimine cross-linked 2- hydroxypopyl-beta-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Int J Nanomater 8: 2101-2117.
123. Shafaq-Zadah M, CS Gomes-Santos, S Bardin, P Maiuri, M Maurin, J Iranzo, A Gautreau, C Lamaze and P Caswell. (2015). Persistent cell migration and adhesion rely on retrograde transport of b(1) integrin. Nat Cell Biol 18: 54-64.
124. Desgrosellier JS and DA Cheresh. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
125. Ikeda Y and K Taira. (2006). Ligand-targeted delivery of therapeutic siRNA. Pharm Res 23:1631-1640.
126. Alam MR, V Dixit, H Kang, ZB Li, X Chen, J Trejo, M Fisher and RL Juliano. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res 36:2764-2776.
127. Han HD, LS Mangala, JW Lee, MMK Shahzad, HS Kim, D Shen, EJ Nam, EM Mora, RL Stone, et al. (2010). Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16:3910-3922.
128. Liu X, W Wang, D Samarsky, L Liu, Q Xu, W Zhang, G Zhu, P Wu, X Zuo, et al. (2014). Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res 42:11805-11817.
129. Huang Y. (2017). Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids 6:116-132.
130. Kruspe S and P Giangrande. (2017). Aptamer-siRNA chimeras: discovery, progress, and future prospects. Biomedicines 5:45.
131. Ni X, M Castanares, A Mukherjee and SE Lupold. (2011). Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18:4206-4214.
132. McNamara JO, ER Andrechek, Y Wang, KD Viles, RE Rempel, E Gilboa, BA Sullenger and PH Giangrande. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005-1015.
133. + T cell decline in humanized mice. Sci Transl Med 3:66ra6.
134. Juliano RL, X Ming and O Nakagawa. (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem 23:147-157.
135. Varkouhi AK, M Scholte, G Storm and HJ Haisma. (2011). Endosomal escape pathways for delivery of Bio- Logicals. Anticancer Res 151:220-228.
136. Endoh T and T Ohtsuki. (2009). Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 61:704-709.
137. Johannes L and V Popoff. (2008). Tracing the retrograde route in protein trafficking. Cell 135:1175-1187.
138. Sandvig K and B van Deurs. (2005). Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther 12:865-872.
139. Sodeik B. (2000). Mechanisms of viral transport in the cytoplasm. Trends Microbiol 8:465-472.
140. Akishiba M, T Takeuchi, Y Kawaguchi, K Sakamoto, HH Yu, I Nakase, T Takatani-Nakase, F Madani, A Gräslund and S Futaki. (2017). Cytosolic antibody delivery by lipidsensitive endosomolytic peptide. Nat Chem 9:751-761.
141. Wadia JS, RV Stan and SF Dowdy. (2004). Transducible TAT-HA fusogenic peptide enhances escape of TATfusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315.
142. Lundberg P, S El-Andaloussi, T Sutlu, H Johansson and U Langel. (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 21:2664-2671.
143. Futaki S, Y Masui, I Nakase, Y Sugiura, T Nakamura, K Kogure and H Harashima. (2005). Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes. J Gene Med 7: 1450-1458.
144. Ahmad A, S Ranjan, W Zhang, J Zou, I Pyykköand PKJ Kinnunen. (2015). Novel endosomolytic peptides for enhancing gene delivery in nanoparticles. Biochim Biophys Acta 1848:544-553.
145. Oliveira S, I van Rooy, O Kranenburg, G Storm and RM Schiffelers. (2007). Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm 331:211-214.
146. Carr CM and PS Kim. (1993). A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73:823-832.
147. Ladokhin AS. (2013). pH-triggered conformational switching along the membrane insertion pathway of the diphtheria toxin T-domain. Toxins 5:1362-1380.
148. Kakimoto S, T Hamada, Y Komatsu, M Takagi, T Tanabe, H Azuma, S Shinkai and T Nagasaki. (2009). The conjugation of diphtheria toxin T domain to poly(ethylenimine) based vectors for enhanced endosomal escape during gene transfection. Biomaterials 30:402-408.
149. Lönn P, AD Kacsinta, X-S Cui, AS Hamil, M Kaulich, K Gogoi and SF Dowdy. (2016). Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. Sci Rep 6:32301.
150. Santos RS, GR Dakwar, E Zagato, T Brans, C Figueiredo, K Raemdonck, NF Azevedo, SC De Smedt and K Braeckmans. (2017). Intracellular delivery of oligonucleotides in Helicobacter pylori by fusogenic liposomes in the presence of gastric mucus. Biomaterials 138:1-12.
151. Zuhorn IS, U Bakowsky, E Polushkin, WH Visser, MCA Stuart, JBFN Engberts and D Hoekstra. (2005). Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol Ther 11:801-810.
152. Du Z, MM Munye, AD Tagalakis, MDI Manunta and SL Hart. (2014). The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations. Sci Rep 4:7107.
153. Heyes J, L Palmer, K Bremner and I MacLachlan. (2005). Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 107:276-287.
154. Convertine AJ, DSW Benoit, CL Duvall, AS Hoffman and PS Stayton. (2009). Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release 133:221-229.
155. Yang B, X Ming, C Cao, B Laing, A Yuan, MA Porter, EA Hull-Ryde, J Maddry, M Suto, WP Janzen and RL Juliano. (2015). High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res 43:1987-1996.
156. Osborn MF, JF Alterman, M Nikan, H Cao, MC Didiot, MR Hassler, AH Coles and A Khvorova. (2015). Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res 43:8664-8672.
157. Ming X, K Carver, M Fisher, R Noel, JC Cintrat, D Gillet, J Barbier, C Cao, J Bauman and RL Juliano. (2013). The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res 41:3673-3687.
158. Oliveira S, MM Fretz, A Høgset, G Storm and RM Schiffelers. (2007). Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. Biochim Biophys Acta 1768:1211-1217.
159. Shiraishi T and PE Nielsen. (2006). Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Lett 580:1451-1456.
160. Dominska M and DM Dykxhoorn. (2010). Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123:1183-1189.
161. Loison F, P Nizard, T Sourisseau, P Le Goff, L Debure, Y Le Drean and D Michel. (2005). A ubiquitin-based assay for the cytosolic uptake of protein transduction domains. Mol Ther 11:205-214.
162. Garcia-Castillo MD, T Tran, A Bobard, H-F Renard, SJ Rathjen, E Dransart, C Lamaze, M Lord, J-C Cintrat, et al. (2015). Retrograde transport is not required for cytosolic translocation B-subunit of Shiga toxin. J Cell Sci 128: 2373-2387.
163. Wittrup A, A Ai, X Liu, P Hamar, R Trifonova, K Charisse, M Manoharan, T Kirchhausen and J Lieberman. (2015). Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol 33:870-876.
164. Gilleron J, W Querbes, A Zeigerer, A Borodovsky, G Marsico, U Schubert, K Manygoats, S Seifert, C Andree, et al. (2013). Image-based analysis of lipid nanoparticlemediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 31:638-646.
165. Li M, Y Tao, Y Shu, JR Larochelle, A Steinauer, D Thompson, A Schepartz, Z Chen and DR Liu. (2015). Discovery and characterization of a peptide that enhances endosomal escape of delivered proteins in vitro and in vivo. J Am Chem Soc 137:14084-14093.
166. Rezgui R, K Blumer, G Yeoh-Tan, AJ Trexler and M Magzoub. (2016). Precise quantification of cellular uptake of cell-penetrating peptides using fluorescence-activated cell sorting and fluorescence correlation spectroscopy. Biochim Biophys Acta 1858:1499-1506.
167. Verdurmen WPR, M Mazlami and A Plückthun. (2017). A quantitative comparison of cytosolic delivery via different protein uptake systems. Sci Rep 7:13194.
168. Milech N, BA Longville, PT Cunningham, MN Scobie, HM Bogdawa, S Winslow, M Anastasas, T Connor, F Ong, et al. (2015). GFP-complementation assay to detect functional CPP and protein delivery into living cells. Sci Rep 5:18329.
169. Cabantous S, TC Terwilliger and GS Waldo. (2005). Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. Nat Biotechnol 23:102-107.
170. Martens TF, K Remaut, J Demeester, SC De Smedt and K Braeckmans. (2014). Intracellular delivery of nanomaterials: how to catch endosomal escape in the act. Nano Today 9:344-364.
171. Hällbrink M, A Florén, A Elmquist, M Pooga, T Bartfai and ÜLangel. (2001). Cargo delivery kinetics of cellpenetrating peptides. Biochim Biophys Acta 1515:101-109.
172. Qian Z, PG Dougherty and D Pei. (2015). Monitoring the cytosolic entry of cell-penetrating peptides using a pHsensitive fluorophore. Chem Commun (Camb) 51:2162-2165.
173. Michalska M and P Wolf. (2015). Pseudomonas exotoxin A: optimized by evolution for effective killing. Front Microbiol 6:963.
174. Seth P, DJ Fitzgerald, MC Willingham and I Pastan. (1984). Role of a low-pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxinepidermal growth factor conjugate. J Virol 51:650-655.
175. Yu P, B Liu and T Kodadek. (2005). A high-throughput assay for assessing the cell permeability of combinatorial libraries. Nat Biotechnol 23:746-751.